IL‐8 were significantly higher in patients with AD (P < 0.001) and had a significant negative effect on all cognitive assessment tests. Plasma levels of IL‐8 level could be a useful biomarker in following AD progression. Here, CXCL8 is linked to Alzheimer disease.